In conclusion, our results suggested that the improved antitumor activity of IL-15-expressing CLDN18.2 CAR-T cells was mediated by their increased in vivo expansion and tumor infiltration promoted possibly by normalization of tumor vasculature. The gene discussed is CLDN18; the disease is neoplasm.